Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface
File version
Accepted Manuscript (AM)
Author(s)
Hutton, ML
Quek, AJ
Klare, WP
Mileto, SJ
Mackin, K
Ly, D
Oorschot, V
Bosnjak, M
Jenkin, G
Conroy, PJ
West, N
Day, CJ
Jennings, MP
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
Background & Aims: The protease plasmin is an important wound healing factor, but it is not clear how it affects gastrointestinal infection–mediated damage, such as that resulting from Clostridioides difficile. We investigated the role of plasmin in C difficile–associated disease. This bacterium produces a spore form that is required for infection, so we also investigated the effects of plasmin on spores. Methods: C57BL/6J mice expressing the precursor to plasmin, the zymogen human plasminogen (hPLG), or infused with hPLG were infected with C difficile, and disease progression was monitored. Gut tissues were collected, and cytokine production and tissue damage were analyzed by using proteomic and cytokine arrays. Antibodies that inhibit either hPLG activation or plasmin activity were developed and structurally characterized, and their effects were tested in mice. Spores were isolated from infected patients or mice and visualized using super-resolution microscopy; the functional consequences of hPLG binding to spores were determined. Results: hPLG localized to the toxin-damaged gut, resulting in immune dysregulation with an increased abundance of cytokines (such as interleukin [IL] 1A, IL1B, IL3, IL10, IL12B, MCP1, MP1A, MP1B, GCSF, GMCSF, KC, TIMP-1), tissue degradation, and reduced survival. Administration of antibodies that inhibit plasminogen activation reduced disease severity in mice. C difficile spores bound specifically to hPLG and active plasmin degraded their surface, facilitating rapid germination. Conclusions: We found that hPLG is recruited to the damaged gut, exacerbating C difficile disease in mice. hPLG binds to C difficile spores, and, upon activation to plasmin, remodels the spore surface, facilitating rapid spore germination. Inhibitors of plasminogen activation might be developed for treatment of C difficile or other infection-mediated gastrointestinal diseases.
Journal Title
Gastroenterology
Conference Title
Book Title
Edition
Volume
159
Issue
4
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2020 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Neurosciences
Nutrition and dietetics
Fibrinolytic System
Liver Enzyme
Microbe
Pathogenic Bacteria
Persistent link to this record
Citation
Awad, MM; Hutton, ML; Quek, AJ; Klare, WP; Mileto, SJ; Mackin, K; Ly, D; Oorschot, V; Bosnjak, M; Jenkin, G; Conroy, PJ; West, N; Day, CJ; Jennings, MP; et al., Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface, Gastroenterology, 2020, 159 (4), pp. 1431-1443.e6